Modality
Peptide
MOA
CD47i
Target
EGFR
Pathway
Innate Imm
LGS
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
~Oct 2018
→ ~Jan 2020
Phase 3
~Apr 2020
→ ~Jul 2021
NDA/BLA
Oct 2021
→ Nov 2030
NDA/BLACurrent
NCT03235206
1,635 pts·LGS
2021-10→2030-11·Not yet recruiting
1,635 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-017mo agoPh1 Dose Esc· LGS
2030-11-144.6y awayPh3 Readout· LGS
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph1 Dose Esc
2025-09-01 · 7mo ago
LGS
Ph3 Readout
2030-11-14 · 4.6y away
LGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03235206 | NDA/BLA | LGS | Not yet recr... | 1635 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| BGN-3859 | BeiGene | Approved | PSMA |